This clinical trial is focused on studying a type of skin cancer called metastatic or unresectable melanoma, which means the cancer has spread to other parts of the body or cannot be removed with surgery. The study is testing a treatment that combines two medications, nivolumab and relatlimab. These medications are given in two different ways: one is a solution for infusion, which is administered directly into a vein, and the other is a solution for injection, which is given under the skin. The purpose of the study is to see if the amount of these medications in the body is the same when given under the skin compared to when given into a vein.
Participants in the study will receive either the intravenous or subcutaneous form of the medication. The study will monitor how the body absorbs the medications and will also look at how well the cancer responds to the treatment. This includes checking if the cancer decreases in size or disappears after treatment. The study will take place over a period of time, and participants will be closely observed to ensure their safety and to gather information about the effectiveness of the treatment.
The trial is open to individuals who have not received prior systemic treatment for their melanoma, except for certain previous therapies if any side effects have stabilized. The study aims to provide valuable information on whether the subcutaneous method of administering the medications is as effective as the intravenous method, potentially offering a more convenient option for patients in the future.
Austria 
Belgium 
Czechia 
Finland 
France 
Germany 
Italy 
Norway 
Poland 
Spain 
Sweden 
